Payment overview · 2025
General Payments
$56.54
3 reported records · 2 companies
Healthcare provider profile · identity verified
Dennis O'Garey Stuart, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LUMBERTON, NC · NPI 1518962521
Verified facts
What the public records show
CMS Open Payments records show Dennis O'Garey Stuart, M.D. received $56.54 in general payments during 2025 across 3 reported records.
Novo Nordisk Inc accounted for 67.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.18 | 67.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.36 | 32.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $56.54 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.18 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 680 | 190 |
| Amlodipine Besylate | Amlodipine Besylate | 561 | 160 |
| Losartan Potassium | Losartan Potassium | 446 | 114 |
| Gabapentin | Gabapentin | 361 | 105 |
| Omeprazole | Omeprazole | 309 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 276 | 59 |
| Potassium Chloride | Potassium Chloride | 255 | 59 |
| Metformin Hcl Er | Metformin Hcl | 247 | 63 |
| Furosemide | Furosemide | 243 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 232 | 57 |
| Carvedilol | Carvedilol | 226 | 56 |
| Allopurinol | Allopurinol | 224 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 217 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 213 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 197 | 52 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 193 | 44 |
| Alendronate Sodium | Alendronate Sodium | 189 | 47 |
| Metformin Hcl | Metformin Hcl | 187 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 179 | 63 |
| Famotidine | Famotidine | 174 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 153 | 49 |
| Tizanidine Hcl | Tizanidine Hcl | 151 | 37 |
| Lisinopril | Lisinopril | 147 | 48 |
| Hydralazine Hcl | Hydralazine Hcl | 142 | 37 |
| Montelukast Sodium | Montelukast Sodium | 140 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 135 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 41 |
| Trazodone Hcl | Trazodone Hcl | 115 | 30 |
| Linzess | Linaclotide | 114 | 31 |
| Trulicity | Dulaglutide | 112 | 15 |
| Ezetimibe | Ezetimibe | 110 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 108 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 32 |
| Eliquis | Apixaban | 105 | 22 |
| Mounjaro | Tirzepatide | 104 | 19 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 103 | 29 |
| Glimepiride | Glimepiride | 102 | 26 |
| Prednisone | Prednisone | 100 | 69 |
| Ropinirole Hcl | Ropinirole Hcl | 97 | 23 |
| Clonidine Hcl | Clonidine Hcl | 96 | 26 |
| Simvastatin | Simvastatin | 96 | 27 |
| Clonazepam | Clonazepam | 95 | 13 |
| Donepezil Hcl | Donepezil Hcl | 95 | 22 |
| Jardiance | Empagliflozin | 91 | 29 |
| Sertraline Hcl | Sertraline Hcl | 91 | 23 |
| Tramadol Hcl | Tramadol Hcl | 91 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 90 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 83 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 23 |
| Alprazolam | Alprazolam | 79 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 23 |
| Ozempic | Semaglutide | 77 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 18 |
| Methocarbamol | Methocarbamol | 76 | 34 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 73 | 15 |
| Meloxicam | Meloxicam | 72 | 18 |
| Lorazepam | Lorazepam | 71 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 69 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 20 |
| Nifedipine Er | Nifedipine | 64 | 16 |
| Pregabalin | Pregabalin | 64 | 17 |
| Cilostazol | Cilostazol | 63 | 14 |
| Farxiga | Dapagliflozin Propanediol | 62 | 14 |
| Mirtazapine | Mirtazapine | 61 | 20 |
| Glipizide | Glipizide | 60 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 58 | 14 |
| Azithromycin | Azithromycin | 55 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 20 |
| Estradiol | Estradiol | 51 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 12 |
| Spironolactone | Spironolactone | 49 | 17 |
| Ibuprofen | Ibuprofen | 48 | 19 |
| Myrbetriq | Mirabegron | 47 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Sucralfate | Sucralfate | 39 | 11 |
| Ramipril | Ramipril | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 13 |
| Glipizide Er | Glipizide | 36 | 11 |
| Rybelsus | Semaglutide | 36 | 12 |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Levemir Flexpen | Insulin Detemir | 32 | 12 |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 16 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 15 |
| Lubiprostone | Lubiprostone | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 18 |
| Mupirocin | Mupirocin | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 15 |
| Insulin Aspart Flexpen | Insulin Aspart | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 14 |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Depakote | Divalproex Sodium | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Norvasc | Amlodipine Besylate | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $56.54 · 3 records | Novo Nordisk Inc | The Cologuard Plus Collection Kit, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error